Related Experiment Video
Updated: Jul 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
SPINK4 modulates inhibition of glycolysis against colorectal cancer progression
Xiaodi Yang1, Sen Jiang2, Zhen Yuan1
1Department of Oncology, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai, China; Key Laboratory of Whole-period Monitoring and Precise Intervention of Digestive Cancer (SMHC), Minhang Hospital and AHS, Fudan University, Shanghai, China.
Abstract:
Dysregulation of glycolysis is frequently linked to aggressive tumor activity in colorectal cancer (CRC). Although serine peptidase inhibitor, Kazal type 4 (SPINK4) has been linked to CRC, its exact linkage to glycolytic processes and gene expression remains unclear. Differentially expressed genes (DEGs) were screened from two CRC-related datasets (GSE32323 and GSE141174), followed by expression and prognostic analysis of SPINK4. In vitro techniques such as flow cytometry, western blotting, transwell assay, and quantitative real-time polymerase chain reaction (qRT-PCR) were used to assess SPINK4 expression in CRC cells. Its effects on apoptosis, glycolysis, and the cell cycle were also investigated. Finally, the impact of SPINK4 overexpression on tumor development was assessed using a xenograft model, while histological and immunohistochemical analyses characterized SPINK4 expression patterns in CRC tissues. SPINK4 expression was downregulated in CRC, correlating with poor patient prognosis. In vitro assays confirmed that overexpression of SPINK4 reduced CRC cell proliferation, invasion, and migration, while its knockdown promoted these processes and caused G1 arrest. SPINK4 also regulated apoptosis by altering caspase activation and Bcl-2 expression. Besides, SPINK4 overexpression altered glycolytic activity, reduced 2-Deoxy-D-glucose (2-DG) absorption, and controlled critical glycolytic enzymes, resulting in alterations in metabolic pathways, whereas SPINK4 knockdown reversed this effect. SPINK4 overexpression significantly reduced tumor volume in vivo, indicating its inhibitory role in carcinogenesis. Moreover, high expression of SPINK4, hexokinase 2 (HK2), glucose transporter 1 (GLUT1), lactate dehydrogenase A (LDHA), and pyruvate kinase M2 (PKM2) was observed in CRC tissues. As a key inhibitor of glycolytic metabolism in CRC, SPINK4 promises metabolic intervention in CRC therapy due to its impact on tumor growth and cell proliferation.
Insights
Serine peptidase inhibitor, Kazal type 4 (SPINK4) is downregulated in colorectal cancer (CRC), inhibiting tumor growth and proliferation. SPINK4 acts as a key inhibitor of glycolytic metabolism, offering potential for CRC metabolic intervention.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Glycolysis dysregulation is linked to aggressive colorectal cancer (CRC) tumor activity.
- Serine peptidase inhibitor, Kazal type 4 (SPINK4) is associated with CRC, but its role in glycolysis and gene expression is unclear.
Purpose of the Study:
- To investigate the role of SPINK4 in colorectal cancer (CRC) progression, focusing on its impact on glycolysis, cell cycle, and apoptosis.
- To analyze SPINK4 expression and its correlation with patient prognosis in CRC.
Main Methods:
- Bioinformatic analysis of CRC datasets (GSE32323, GSE141174) to screen differentially expressed genes (DEGs) and analyze SPINK4 expression and prognosis.
- In vitro studies using flow cytometry, western blotting, transwell assays, and qRT-PCR to assess SPINK4's effects on CRC cell proliferation, invasion, migration, apoptosis, cell cycle, and glycolysis.
- In vivo xenograft models and histological/immunohistochemical analyses to evaluate SPINK4's impact on tumor development and expression patterns in CRC tissues.
Main Results:
- SPINK4 expression was found to be downregulated in CRC tissues and correlated with poor patient prognosis.
- SPINK4 overexpression inhibited CRC cell proliferation, invasion, and migration, induced G1 arrest, and promoted apoptosis.
- SPINK4 overexpression reduced glycolytic activity, 2-Deoxy-D-glucose (2-DG) absorption, and modulated key glycolytic enzymes (HK2, GLUT1, LDHA, PKM2), significantly reducing tumor volume in vivo.
- SPINK4 knockdown reversed these effects, promoting CRC progression.
Conclusions:
- SPINK4 acts as a tumor suppressor in colorectal cancer by inhibiting proliferation, invasion, migration, and glycolysis.
- SPINK4's downregulation in CRC suggests its potential as a prognostic biomarker.
- SPINK4's role as a key inhibitor of glycolytic metabolism presents therapeutic opportunities for CRC intervention.
Related Concept Videos
Inhibition of Cdk Activity
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Gene Regulation During Sporulation

